185 related articles for article (PubMed ID: 35370235)
1. Successful Control of Hypercalcemia with Sorafenib, Evocalcet, and Denosumab Combination Therapy for Recurrent Parathyroid Carcinoma.
Makino H; Notsu M; Asayama I; Otani H; Morita M; Yamamoto M; Yamauchi M; Nakao M; Miyake H; Araki A; Uchino S; Kanasaki K
Intern Med; 2022 Nov; 61(22):3383-3390. PubMed ID: 35370235
[TBL] [Abstract][Full Text] [Related]
2. Control of Refractory Hypercalcemia with Denosumab in a Case of Metastatic Parathyroid Carcinoma.
Çalapkulu M; Gul OO; Cander S; Ersoy C; Erturk E; Sagiroglu MF; Saraydaroglu O
J Coll Physicians Surg Pak; 2020 Jul; 30(7):757-759. PubMed ID: 32811610
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia.
Fountas A; Andrikoula M; Giotaki Z; Limniati C; Tsakiridou E; Tigas S; Tsatsoulis A
Endocr Pract; 2015 May; 21(5):468-73. PubMed ID: 25667369
[TBL] [Abstract][Full Text] [Related]
4. Denosumab for the Treatment of Hypercalcemia in a Patient With Parathyroid Carcinoma: A Case Report.
Roukain A; Alwan H; Bongiovanni M; Sykiotis GP; Kopp PA
Front Endocrinol (Lausanne); 2021; 12():794988. PubMed ID: 35173680
[TBL] [Abstract][Full Text] [Related]
5. Denosumab for management of parathyroid carcinoma-mediated hypercalcemia.
Vellanki P; Lange K; Elaraj D; Kopp PA; El Muayed M
J Clin Endocrinol Metab; 2014 Feb; 99(2):387-90. PubMed ID: 24178790
[TBL] [Abstract][Full Text] [Related]
6. Successful palliation of hypercalcemia secondary to metastatic parathyroid cancer: an unusual indication for hepatic resection.
Mezhir JJ; Melis M; Headley RC; Pai RK; Posner MC; Kaplan EL
J Hepatobiliary Pancreat Surg; 2007; 14(4):410-3. PubMed ID: 17653642
[TBL] [Abstract][Full Text] [Related]
7. Denosumab treatment for refractory hypercalcemia in a hemodialysis patient with tertiary hyperparathyroidism.
Zhang P; Yu Y; Gao Y; Yuan G; Zhang J; Wang W
Hemodial Int; 2023 Apr; 27(2):E23-E28. PubMed ID: 36719850
[TBL] [Abstract][Full Text] [Related]
8. Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab.
Karuppiah D; Thanabalasingham G; Shine B; Wang LM; Sadler GP; Karavitaki N; Grossman AB
Eur J Endocrinol; 2014 Jul; 171(1):K1-5. PubMed ID: 24743399
[TBL] [Abstract][Full Text] [Related]
9. Effect of early dose increase of evocalcet for intractable hypercalcemia caused by parathyroid carcinoma.
Morishita A; Hozumi Y; Ishii H; Hokazono Y; Manuel Yosei Kikuchi C; Shimasaki M; Itaya M; Oura M; Kuriki K; Hishida A; Seki G
Endocrinol Diabetes Metab Case Rep; 2023 Jan; 2023(1):. PubMed ID: 36602916
[TBL] [Abstract][Full Text] [Related]
10. [Parathyroid carcinoma. Therapeutic strategies derived from 20 years of experience].
Pelizzo MR; Piotto A; Bergamasco A; Rubello D; Casara D
Minerva Endocrinol; 2001 Mar; 26(1):23-9. PubMed ID: 11323564
[TBL] [Abstract][Full Text] [Related]
11. Effective long-term management of parathyromatosis-related refractory hypercalcemia with a combination of denosumab and cinacalcet treatment.
Tzotzas T; Goropoulos A; Karras S; Terzaki A; Siolos A; Doumas A; Zaramboukas T; Tigas S
Hormones (Athens); 2022 Mar; 21(1):171-176. PubMed ID: 34993886
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism.
Takeuchi Y; Takahashi S; Miura D; Katagiri M; Nakashima N; Ohishi H; Shimazaki R; Tominaga Y
J Bone Miner Metab; 2017 Nov; 35(6):616-622. PubMed ID: 27873072
[TBL] [Abstract][Full Text] [Related]
13. Recurrent hypercalcemia due to ectopic production of parathyroid hormone-related protein and intact parathyroid hormone in a single patient with multiple malignancies.
Eid W; Wheeler TM; Sharma MD
Endocr Pract; 2004; 10(2):125-8. PubMed ID: 15256329
[TBL] [Abstract][Full Text] [Related]
14. Use of denosumab in parathyroid carcinoma with refractory hypercalcemia.
Tong CV; Hussein Z; Noor NM; Mohamad M; Ng WF
QJM; 2015 Jan; 108(1):49-50. PubMed ID: 25099611
[No Abstract] [Full Text] [Related]
15. Resistant hypercalcaemia in metastatic parathyroid carcinoma.
Bowyer SE; White AM; Ransom DT; Davidson JA
Med J Aust; 2013 Jun; 198(10):559-61. PubMed ID: 23725272
[No Abstract] [Full Text] [Related]
16. A case of parathyroid carcinoma with hypercalcemia responsive to cinacalcet therapy.
Szmuilowicz ED; Utiger RD
Nat Clin Pract Endocrinol Metab; 2006 May; 2(5):291-6; quiz 297. PubMed ID: 16932300
[TBL] [Abstract][Full Text] [Related]
17. Parathyroid carcinoma: difficult management options.
Bhansali A; Kataria RN; Dutta P; Saha MM; Singh P; Dash RJ
Indian J Cancer; 2002; 39(3):119-22. PubMed ID: 12928568
[TBL] [Abstract][Full Text] [Related]
18. Parathyroid carcinoma: Single centre experience.
Cunha C; Pinheiro SL; Donato S; Tavares Bello C; Simões H; Nunes Silva T; Prazeres S; Doutel D; Cavaco BM; Leite V
Clin Endocrinol (Oxf); 2022 Sep; 97(3):250-257. PubMed ID: 35120263
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid carcinoma: a case with recurrence treated with extensive vascular surgery to the neck.
Qvist N; Krøll L; Ladefoged C; Blichert-Toft M; Rohr N
Eur J Surg Oncol; 1986 Jun; 12(2):187-91. PubMed ID: 3011517
[TBL] [Abstract][Full Text] [Related]
20. Resection of pulmonary metastasis from parathyroid carcinoma.
Hundley JC; Albertson DA; Bradley RF; Levine EA
Am Surg; 2003 Sep; 69(9):779-83. PubMed ID: 14509326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
